TABLE 2.
CVID Subjects with lymphoma, location, treatment and outcomes
| Subject | Age at lymphoma diagnosis (years)/sex | Lymphoma type (subtypes or cell-of-origin when known) | Location/Site | Treatment & outcomes (Regimen specified when known) | Age at death (years) or alive, age |
|---|---|---|---|---|---|
| 1 | 40/M | NHL, B-cell NOS | Stomach | Died due to lymphoma-related complications | Died age 42 |
| 2 | 62/M | EBV+ DLBCL, NOS | Spleen, lymph nodes | Chemotherapy; Died due to lymphoma-related complications | Died age 62 |
| 3 | 74/M | DLBCL (Germinal Center B-cells) | Mediastinum | Died due to lymphoma-related complications | Died age 74 |
| 4 | 1st 4 M | 1st: Hodgkin lymphoma | NA | Chemotherapy | Died age 25 |
| 2nd 24/F | 2nd: NHL, B-cell | Lymph nodes | Died due to lymphoma-related complications | ||
| 5 | 59/F | MALT | Parotid gland | NA | Alive at last encounter |
| 6 | 46/F | Extranodal MZL | Lung | No treatment given; Died due to complications of PML | Died age 48 |
| 7 | 53/M | DLBCL (T-cell/histiocyte rich B-cell lymphoma) | Liver | Chemotherapy | Alive age 73 |
| 8 | 81/F | NHL, B-cell | Jejunum | Chemotherapy Died due to lymphoma-related complications |
Died age 83 |
| 9 | 38/M | Extranodal MZL | Abdomen | Chemotherapy; Died due to lymphoma-related complications involving lung, liver and malnutrition | Died age 38 |
| 10 | 71/F | DLBCL, NOS | Lung, lymph nodes | C-MOPP; Died due to lymphoma-related complications | Died age 72 |
| 11 | 43/M | DLBCL, NOS | Small bowel | Surgical resection and chemotherapy | Alive age 53 |
| 12 | 42/F | NHL, B-cell | Lymph nodes | Chemotherapy; Died due to lymphoma-related complications | Died age 42 |
| 13 | NA/F | Extranodal; MZL | Lung | NA | Alive at last encounter |
| 14 | 19/F | DLBCL; EBV+ | Lymph nodes supraclavicular | DA-EPOCH; R-COPAD; EBV CTL therapy, bone marrow transplant | Alive at 20 |
| 15 | 71/F | DLBCL, NOS | Thyroid | CHOP | Alive age 71 |
| 16 | 1st 56 | 1st MALT | Parotid gland | Surgical parotid node removal and RT | Died age 71 |
| 2nd 67/F | 2nd Follicular B-cell lymphoma | Axilla and mediastinum | R-CHOP; Died due to lymphoma-related complications | ||
| 17 | 11/M | Hodgkin lymphoma | Lung | MOPP-ABVD | Alive age 35 |
| 18 | NA/F | NHL, B-cell | NA | NA | Alive at last encounter |
| 19 | 34/F | MALT | Cheek, parotid gland | Surgical node removal, no chemotherapy | Alive age 54 |
| 20 | 1st child | 1st Hodgkin lymphoma | NA | Chemotherapy | Died age 41 |
| 2nd 39/M | 2nd: NHL, B-cell | Brain | CHOP and stem cell transplantation; Died due to lymphoma-related complications | ||
| 21 | 51/F | DLBCL, NOS | Lung, lymph nodes | Chemotherapy; Died due to lymphoma-related complications | Died age 55 |
| 22 | 56/F | DLBCL NFIL (Intermediate-grade diffuse, small-cleaved cell) | Lymph nodes (pelvic) | M-BACOD, CHOP, CP, RT | Alive at last encounter |
| 23 | 41/M | DLBCL, NOS | Lymph nodes (abdominal and pelvic) | R-CHOP | Alive age 51 |
| 24 | 48/F | DLBCL, NOS | Proximal jejunum | Surgical resection | Died, age 50 of other causes |
| 25 | 46/M | MALT lymphoma | Parotid | not treated | Died age 48 |
| 26 | 1st 10 | 1st Hodgkin lymphoma | NA | Chemotherapy | Died age 26 |
| 2nd 25/M | 2nd NHL, B-cell | Lymph nodes | CHOP; Died due to complications related to undiagnosed neurodegenerative disease | ||
| 27 | 53/F | DLBCL, NOS | Pelvis, spine | R-CHOP | Alive age 57 |
| 28 | 77/M | NHL, B-cell | Lymph node | Chemotherapy; Died due to lymphoma-related complications | Died age 79 |
| 29 | 43/F | Extranodal MZL | Kidney | Partial nephrectomy; R-CHOP | Alive age 46 |
| 30 | 70/F | NHL, B-cell | Lung | Chemotherapy; Died due to lymphoma-related complications involving severe lung disease | Died age 72 |
| 31 | 45/M | Plasmacytoid lymphoma, IgA+ | Jejunum | Surgical resection; R-CHOP; Died due to lymphoma-related complications | Died age 47 |
| 32 | 65/F | DLBCL, NOS | Diffuse, bone marrow | CHOP; Died due to lymphoma-related complications | Died age 67 |
| 33 | NA/F | NHL, B-cell | NA | Chemotherapy | Died age 67 |
| 34 | 51/M | DLBCL, NOS | Lymph nodes | Chemotherapy; Died due to lymphoma-related complications | Died age 57 |
| 35 | 66/F | EBV+ T cell rich DLBCL, NOS | NA | NA | Died age 68 |
| 36 | 59/F | DLBCL, Intermediate-grade NHL (Diffuse, mixed small and large cell)b | Lung | RT, Chemotherapy; Died due to lymphoma-related complications | Died age 65 |
| 37 | 54/F | DLBCL, Intermediate-grade NHL (Diffuse, mixed small and large cell)b DLBCL, NOS; IgM-kappa macroglobulinemia | Lymph nodes (pelvic) | Chemotherapy; Died due to lymphoma-related complications | Died age 58 |
| 38 | 64/F | DLBCL, NOS | Supraclavicular area and abdomen | C-MOPP; Died due to lymphoma-related complications | Died age 68 |
| 39 | 58/F | DLBCL, Intermediate-grade NHL (Diffuse, mixed small and large cell)b | Right inguinal lymph node | Surgical resection, CHOP; Died 15 years later due to unrelated causes | Died age 69 |
| 40 | 75/F | Anaplastic large T-cell lymphoma, ALK-negative | Lymph nodes (pelvic) | CHOEP, ICE | Alive age 80 |
| 41 | 46/F | Extranodal MZL; MBL | Abdominal mass above kidney | R-CHOP, 4 years after diagnosis | Alive age 55 |
| 42 | 12/F | DLBCL, NOS | Liver, spleen | CHOP; Died due to lymphoma-related complications | Died age 13 |
| 43 | 46/M | MALT | Lung | CVP–R, stem cell transplantation | Alive age 64 |
| 44 | 34/F | DLBCL, NOS | Lymph nodes (pelvic) | R-CHOP | Alive age 37 |
| 45 | 68/F | DLBCL, NOS | Lung, lymph nodes | R-EPOCH | Alive age 72 |
Note: Abbreviations: ABVD, doxorubicin (adriamycin), bleomycin, vinblastine, dacarbazine; ALK, Anaplastic lymphoma kinase; CHOEP, cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (oncovin), etoposide, prednisone; CHOP, cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (oncovin), prednisone; C-MOPP, cyclophosphamide, vincristine (oncovin), procarbazine, prednisone; CP, chlorambucil, prednisone; CVP, cyclophosphamide, vincrinstine, prednisone; DA=dosage adjusted; DLBCL, diffuse B-cell lymphoma (NOS, not otherwise specified); HD, Hodgkin lymphoma; ICE, ifosfamide, carboplatin, etoposide; MALT, mucosal-associated lymphoid tissue; M-BACOD, high-dose methotrexate, bleomycin (adriamycin), doxorubicin, cyclophosphamide, vincristine (oncovin), dexamethasone; MBL, Monoclonal B-Cell Lymphocytosis; MOPP, nitrogen mustard, vincristine (oncovin), procarbazine, prednisone; MZL, marginal zone lymphoma; NA, information not available; NHL, non-Hodgkin lymphoma; PML, Progressive multifocal leukoencephalopathy; R-CHOP, rituximab, cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (oncovin), prednisone; R-COPAD, (rituximab, cyclophosphamide, vincristine, prednisolone and doxorubicin); R-EPOCH, rituximab, etoposide, prednisone, vincristine (oncovin), cyclophosphamide, doxorubicine (hydroxydaunomycin); R-EPOCH, rituximab, etoposide, prednisone, vincristine, oncovin, cyclophosphamide, doxorubicin; RT, radiation therapy.
Diagnosis was made prior to the fourth edition World Health Organization (WHO) classification.
Classification according to the National Cancer Institute’s Working Formulation (IWF) (Rosenberg et. al 1982)